Related Experiment Video

Updated: Dec 7, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Connor O'Leary1,2,3, Harry Gasper1, Katherine B Sahin2,3

  • 1Princess Alexandra Hospital, Brisbane 4000, Australia.

Pharmaceuticals (Basel, Switzerland)
|September 30, 2020
PubMed

Insights

Epidermal growth factor receptor (EGFR) mutations drive non-small-cell lung cancer (NSCLC). While EGFR inhibitors improve outcomes, combinations and adjuvant therapies show limited benefit, and liquid biopsy shows promise for monitoring resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small-cell lung cancer (NSCLC).
  • Distinct tumor biology exists between EGFR-mutant and wild-type NSCLC subtypes.
  • Targeted EGFR therapies offer superior outcomes in advanced NSCLC compared to traditional chemotherapy.

Purpose of the Study:

  • To review current advancements in EGFR-mutant NSCLC treatment.
  • To evaluate the efficacy of combination therapies and adjuvant EGFR inhibitors.
  • To explore the emerging role of liquid biopsy in managing NSCLC.

Main Methods:

  • Review of clinical trial data and scientific literature on EGFR-mutant NSCLC.
  • Analysis of outcomes for monotherapy, combination therapies, and adjuvant EGFR inhibitors.
  • Assessment of the potential of liquid biopsy for early detection of resistance and progression.

Main Results:

  • EGFR inhibitors as monotherapy improve outcomes in advanced NSCLC.
  • Combination therapies with EGFR inhibitors have yielded varied results, with no clear first-line standard.
  • Adjuvant EGFR inhibitors have not yet demonstrated significant improvements in overall survival.
  • Liquid biopsy shows potential for identifying early resistance mechanisms and disease progression.

Conclusions:

  • Single-agent EGFR inhibitors remain a cornerstone for first-line treatment in advanced EGFR-mutant NSCLC.
  • Further research is needed to optimize combination strategies and adjuvant settings.
  • Liquid biopsy represents a promising tool for personalized NSCLC management and monitoring treatment response.
Keywords:
EGFRcirculating tumor cellsepidermal growth factor receptornon-small-cell lung cancertyrosine kinase inhibitors

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
84.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K